-
Acyclovir will go to the United States, and the domestic market is very hot
Time of Update: 2018-04-17
With the arrival of spring, various viruses began to be active after the weather turned warm Herpes zoster virus is one of them At this time, the infection becomes very strong The elderly and people w
-
Gone against the weather! The net profit of humanwell medicine soared 148.5%, and the three drugs led the 10 billion market
Time of Update: 2018-04-16
Wonderful content yesterday, humanwell pharmaceutical released its 2017 annual report The group's operating revenue was 15.446 billion yuan, an increase of 25.26% year-on-year; the net profit attribut
-
How many games can xiumeile win in the "King's glory"?
Time of Update: 2018-04-12
In the list of global top 10 drug sales in 2017, Humira (adamumumab) Co., Ltd of abbvie won the title with us $18.427 billion, which is the sixth consecutive year that Humira has won the title of "dru
-
Two 2 billion products in hand, three chemical drugs in East China Pharmaceutical 1.1 in research projects
Time of Update: 2018-04-12
In recent days, Huadong pharmaceutical has released the latest performance In 2017, its operating revenue reached 27.832 billion yuan, an increase of 9.66% over the previous year The net profit attrib
-
The market of 20 billion digestive and metabolic drugs, the growth rate of "tetin" is as high as 46%
Time of Update: 2018-04-10
April 9 is the international day of protecting stomach According to the data released by WHO, the incidence rate of gastric diseases worldwide is 80%, and it is growing at 17.43% annually In recent ye
-
More than 350 billion in revenue is not enough! Sinopharm group plans to launch the seventh listed company
Time of Update: 2018-04-08
With the intensive disclosure of the annual reports of listed companies, the 2017 performance of six listed companies under Sinopharm group, including Sinopharm holding, Sinopharm, Sinopharm and Sinop
-
Junshi biological PD-1 monoclonal antibody applied for listing, and the first three generic drugs were approved
Time of Update: 2018-04-04
Abstract: in the first quarter of 2018, the application for drug registration showed a significant growth trend Junshi biological PD-1 monoclonal antibody trepril monoclonal antibody injection was app
-
March: 2 NDA, 11 ind
Time of Update: 2018-04-03
In March, 11 products were involved in the clinical application for new drugs, and another two applications for new drugs were rimazolum of Hengrui medicine and utidelon injection of Huahao Zhongtian
-
The top 10-year sales of chemical injection exceed 3 billion yuan. Who can break through 21 class 1 "new drugs"?
Time of Update: 2018-04-02
Recently, the drug evaluation center (CDE) of the State Food and Drug Administration issued the technical guidance on drug injection research and development, which is applicable to chemical injection
-
Nonalcoholic fatty liver disease (NAFLD) is on the rise, attacking nearly 50 billion highlands of liver disease
Time of Update: 2018-04-01
With the improvement of people's living standards, fatty liver has become a multiple disease in China On December 2, 2016, the national government issued the clinical pathway of nonalcoholic fatty liv
-
The R & D investment of Shanghai Pharmaceutical Co., Ltd. has reached a new high repeatedly, focusing on the development of these seven new drugs in 2018
Time of Update: 2018-04-01
On March 23, SHP released its 2017 annual report (hereinafter referred to as the annual report): the company's revenue was 130.847 billion yuan, an increase of 8.35% year on year; the net profit attri
-
The "anti-cancer drug PD-1" is strong. Who will be the first domestically marketed PD-1/PD-L1 drug?
Time of Update: 2018-03-30
none="shifuMouseDownStyle('shifu_bus_005')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-
-
Cinda has voluntarily withdrawn the application for listing of PD-1! Yu Dechao responds. Who is the "first child" in this new drug tide?
Time of Update: 2018-03-29
On March 27, the news of "Xinda mAb was dissuaded" came out of the circle of friends Today, e-drug managers confirmed from reliable channels that Cinda biology did withdraw its application for listing
-
Anti cancer medicine for zero tax rate! These five heavy imported new drugs have a strong impact on the anti-cancer Market
Time of Update: 2018-03-25
On the morning of March 20, after the closing of the first session of the 13th National People's Congress, in response to questions from Chinese and foreign journalists, the premier of the State Counc
-
A panoramic observation of imported new drugs approved by CFDA in 2017 (1)
Time of Update: 2018-03-23
Based on the published data of CFDA / CDE, the new chemical drugs (NME / and its compound drugs) and biological drugs (BLA) were combined After searching on CFDA and CDE official websites, the author
-
21 "China class 1" antitumor drugs under research in clinical phase III (Part I)
Time of Update: 2018-03-21
Phase III clinical research is like a football match The success or failure is always at one stroke Anti-tumor drugs are the hottest direction of drug research and development at present, and are fav
-
In recent years, the "Chinese Academy of Sciences System" ~ Drug Registration
Time of Update: 2018-03-19
I remember how I wanted to be a member of CAS as early as I was a undergraduate, and I hope to devote my youth and life to it I feel that it will be a very meaningful thing..
-
Understand the development prospect of China's biopharmaceutical Market: who can take the lead in biopharmaceutics? Hengrui has the absolute advantage of PD-1
Time of Update: 2018-03-19
Biopharmaceutics is one of the fastest growing sub industries in the pharmaceutical industry in recent years The global market size is expected to rise from US $2020 billion in 2016 to US $326 billion
-
Hospital cardiovascular drugs top 10! A close look at the competition pattern of enterprises
Time of Update: 2018-03-18
In the middle and late 20th century, after the annual sales volume of cardiovascular drugs exceeded that of anti infective drugs, the trend of continuous and stable growth has always appeared At prese
-
On the highlights and R & D investment of Hengrui pharmaceutical product line
Time of Update: 2018-03-16
Photo source: Recently, Hengrui announced that it will carry out phase III clinical trial of bevacizumab injection in the near future It seems that the payback period of 32.9 million yuan of R & D inv
